The syngeneic ovarian cancer model is an experimental system that uses genetically identical mice injected with ovarian cancer cells to replicate the tumor microenvironment. Alfa Cytology specializes in developing these models, offering researchers customized syngeneic ovarian cancer models to facilitate precise studies of tumor biology and the evaluation of novel therapies.
The syngeneic ovarian cancer model uses genetically identical mice to implant murine ovarian cancer cells, allowing study of tumor growth, progression, and tumor-host immune interactions within a consistent genetic background. Unlike xenograft models, syngeneic models retain an intact immune system, making them ideal for studying immune responses and escape mechanisms. This model is crucial for evaluating new immunotherapies and understanding natural tumor biology.
Fig.1 The process of constructing syngeneic cancer models. (LYUBETSKAYA A, et al., 2022)
Cell or tissue sources in the syngeneic ovarian cancer model must meet specific requirements and characteristics.
Alfa Cytology offers comprehensive syngeneic ovarian cancer model development services, encompassing everything from cell line selection to model evaluation. Our objective is to provide researchers with a reliable experimental platform that enables efficient ovarian cancer studies, facilitating the development of new therapies and a deeper understanding of tumor biology.
Mouse Strain Selection
Select suitable syngeneic mouse lines based on research objectives and specific needs, ensuring their genetic background matches the target tumor cell line. This enhances the reliability and validity of the experiment.
Cell Line Acquisition and Culture
Obtain validated ovarian cancer cell lines and culture them under stringent aseptic conditions. Use standard culture media, changing it regularly to maintain cell activity and proliferation. Monitor cell morphology and growth to ensure stability and consistency.
Tumor Cell Injection and Monitoring
Prepare and dilute tumor cells for injection. Anesthetize mice, then inject cells intraperitoneally or subcutaneously. Regularly monitor tumor growth using ultrasound or computed tomography (CT), and record changes in volume, growth rate, and morphology.
Pharmacodynamic Analysis
Pharmacodynamic assays in ovarian cancer are designed to evaluate the effects of drugs on cancer cell growth and survival. These typically include cell proliferation assays (e.g., MTT or CCK-8), apoptosis assays (flow cytometry), cell cycle analyses, and migration and invasion assays (e.g., scratch or transwell assays).
Case Study
Our established syngeneic orthotopic model platform leverages immunocompetent mice and murine-derived tumor cells, providing the essential gold-standard system for investigating the tumor immune microenvironment and evaluating novel immunotherapies.
Cell Line: ID8-luc cell line
Age: 7-8 weeks
Weight: 20-22 g
Species: C57BL/6
Sex: Female
Fig. 2 Establishment of syngeneic ovarian cancer model
Utilizes C57BL/6 mice to enable the study of complex tumor-immune interactions. Intraperitoneal injection of tumor cells (ID8-Luc) reliably induces peritoneal carcinomatosis and malignant ascites accumulation, mirroring advanced human disease within 6-10 weeks.
Following orthotopic transplantation, tumor growth and metastasis in mice were continuously monitored via in vivo bioluminescence imaging. In later stages, localized metastatic spread of tumor cells within the peritoneal cavity was observed (Figure 3). Survival curves for the mouse model are shown in Figure 4.
Fig. 3 In vivo bioluminescence imaging of tumor burden.
Fig. 4 Survival analysis of the ovarian cancer peritoneal metastases model.
With accumulated extensive experience in the development of syngeneic ovarian cancer models and, Alfa Cytology provides you with comprehensive experimental support and assistance. If you have any questions or need further information, please feel free to contact us; we are here to help.
Reference
For research use only.
Alfa Cytology, located in New York, specializes in preclinical research solutions to support ovarian cancer therapy development, offering a streamlined process from target discovery to IND application.
Copyright © 2026 Alfa Cytology. All rights reserved.
